A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 8, 2013, Pages 1364-1373

  Spillane, Susan ^a   Bennett, Kathleen ^a   Sharp, Linda ^b   Barron, Thomas I ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EXPOSURE; FEMALE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOCIAL STATUS; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IRELAND; MALE; METFORMIN; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84882273707     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0347     Document Type: Article

References (37)

1. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2012;156:218-31.
2. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010;49:662-71.
3. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, et al. Metformin suppresses intestinal polyp growth in ApcMin/? mice. Cancer Sci 2008;99:2136-41.
4. Lea MA, Chacko J, Bolikal S, Hong JY, Chung R, Ortega A, et al. Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin. Anticancer Res 2011;31:421-6.
5. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010;17:351-60.
6. Habibollahi P, van den Berg NS, Kuruppu D, Loda M, Mahmood U. Metformin-an adjunct antineoplastic therapy-divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med 2013; 54:252-8.
7. Feng YH,Wu CL, Shiau AL, Lee JC, Chang JG, Lu PJ, et al. MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med 2012;29:920-6.
8. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
9. Pollak MN. Investigating metformin for cancer prevention and treatment: The end of the beginning. Cancer Discov 2012;2:778-90.
10. Martin M, Marais R. Metformin: A diabetes drug for cancer, or a cancer drug for diabetics? J Clin Oncol 2012;30:2698-700.
11. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012;18:2905-12.
12. Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, et al. Metformin intake is associated with better survival in ovarian cancer: A case-control study. Cancer 2013;119:555-62.
13. Tan BX, Yao WX, Ge J, Peng XC, Du XB, Zhang R, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011;117:5103-11.
14. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee M-H, Yeung S-CJ. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2? breast cancer. Ann Oncol 2012;23:1771-80.
15. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012;106:1374-8.
16. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012;131:752-9.
17. Suissa S, Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 2012;35:2665-73.
18. Burke P. Primary Care Reimbursement Service; Statistical Analysis of Claims and Payments 2010. Health Service Executive; 2010. Available from: Http://www.hse.ie/eng/staff/PCRS/PCRS-Publications/claimsandpayments2010.pdf. [Accessed 2013 Mar 27].
19. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs. Oslo. Norway; 2012 [Accessed Mar 27 2013]. Available from: Www.whocc.no/atc-ddd-index.
20. Greene F, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
21. Kourelis TV, Siegel RD. Metformin and cancer: New applications for an old drug. Med Oncol 2012;29:1314-27.
22. Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how? Diabetes Obes Metab 2012;14:579-85.
23. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12.
24. Punt CJA, Buyse M, Kohne C-H, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: A systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007;99:998-1003.
25. Kelly A, Teljeur C. The national deprivation index for health & health services research. Small Area Health Research Unit, Technical Report; 2007, Trinity College Dublin, Ireland.
26. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 2012;9:561-70.
27. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154:854-64.
28. Zhang X, Loberiza FR, Klein JP, Zhang M-J. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed 2007; 88:95-101.
29. Shrier I, Platt R. Reducing bias through directed acyclic graphs. BMC Med Res Methodol 2008;8:70.
30. Textor J, Hardt J, Knuppel S. DAGitty: A graphical tool for analyzing causal diagrams. Epidemiology 2011;22:745.
31. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-36.
32. Vansteelandt S, Bekaert M, Claeskens G. On model selection and model misspecification in causal inference. Stat Methods Med Res 2012;21:7-30.
33. Ioannou GN, Boyko EJ. Metformin and colorectal cancer risk in diabetic patients. Diabetes Care 2011;34:2336-7.
34. Goodwin P, Stambolic V, Lemieux J, Chen B, Parulekar W, Gelmon K, et al. Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011;126:215-20.
35. Kuiper JG, Phipps AI, Neuhouser ML, Chlebowski RT, Thomson CA, Irwin ML, et al. Recreational physical activity, body mass index, and survival in women with colorectal cancer. Cancer Causes Control 2012;23:1939-48.
36. Rickles AS, Iannuzzi JC, Mironov O, Deeb AP, Sharma A, Fleming FJ, et al. Visceral obesity and colorectal cancer: Are we missing the boat with BMI? J Gastrointest Surg 2012;17:133-43.
37. Vrieling A, Kampman E. The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: A review of the literature. Am J Clin Nutr 2010;92:471-90.